monoclonal antibody

TWiV 984: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses the political polarization of COVID-19 treatments among physicians and laypeople in the United States, seven alternatives to evidence-based medicine, Malawi’s cholera death toll crosses 1,300 in its deadliest outbreak on record, impact of coronavirus infections on pediatric patients at a tertiary pediatric hospital, maternal mRNA COVID-19 vaccination during …

TWiV 984: Clinical update with Dr. Daniel Griffin Read More »

TWiV 953: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses high demand for Amoxicillin causing shortages amid child RSV surge, epidemiologic and clinical features of children and adolescents aged <18 years with monkeypox, low risk of SARS-Cov-2 transmission by fomites, nucleocapsid antigenemia is a marker of acute SARS-CoV-2 infection, impact of community masking on COVID-19,  protection against Omicron from vaccination and …

TWiV 953: Clinical update with Dr. Daniel Griffin Read More »

Jake Scott put the ID in COVID-19

Infectious Disease physician Jake Scott joins TWiV to provide a west coast clinical perspective on the evolution of the COVID-19 pandemic with respect to the impact of vaccines, antivirals, variants of concern and mortality. Hosts: Vincent Racaniello, Alan Dove, Rich Condit,  and Kathy Spindler Guest: Jake Scott Click arrow to playDownload TWiV 952 (63 MB .mp3, 104 …

Jake Scott put the ID in COVID-19 Read More »

TWiV 951: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses Influenza incidence and vaccine effectiveness during the southern hemisphere influenza season in Chile, Nirsevimab for prevention of RSV infection in healthy late-preterm and term infants, severe Monkeypox in hospitalized patients, reinfections with different SARS-CoV-2 Omicron subvariants, impact of community masking on COVID-19 in Bangladesh, unadjuvanted intranasal spike vaccine elicits protective …

TWiV 951: Clinical update with Dr. Daniel Griffin Read More »

TWiV 949: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Pakistan, polio by the numbers , influenza and COVID-19 vaccination coverage among health care personnel, phase 1/2a safety and immunogenicity of an adenovirus 26 vector RSV vaccine encoding prefusion F in adults 18–50 years and RSV seropositive children 12–24 months, receipt of first and second doses of JYNNEOS vaccine for prevention of Monkeypox, distinguishing SARS-CoV-2 persistence and reinfection, Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages, association between regular physical activity and the protective effect of vaccination against SARS-CoV-2 in a South African case, COVID-19 outcomes in solid organ transplant recipients who received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab treatment, Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralizing antibodies, and Tocilizumab versus Baricitinib in hospitalized patients with severe COVID-19.

TWiV 947: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses the prediction of upcoming global infection burden of influenza seasons after relaxation of public health and social measures during the COVID-19 pandemic, severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters, and how successful immunomodulators for treatment of COVID-19 have opened the pathway for comparative trials.

Scroll to Top